A Novel Oral Biologic in the treatment of Psoriasis

Alla Arzumanyan, PhD\*, Ira C. Spector, PhD\* and Daniel, N Sauder MD+ SFA Therapeutics, \* Jenkintown, PA Toronto Dermatology Associates+, Toronto, Ontario, Canada

SFA Therapeutics Inc. is a clinical stage biotech company that develops drugs based

on selective bacterial metabolites to treat chronic inflammatory and autoimmune

diseases. In this study we used SFA-002 which has anti-inflammatory and

properties and has been shown to upregulate IL-10.

In this Phase 1b trial (NCT05642182) we examined the effect of SFA-002 in an

open label prospective study on psoriasis. The study protocol was a 12-week study

with active drug and a 1 month follow up with an optional 12-week extension.

In the 14 evaluable subjects (including 6 subjects on a 3-month extension) we

demonstrated that 92% of patients demonstrated a PASI improvement of great than

50, 72% of subjects demonstrated an improvement of PASI of greater than 75.

Two subjects achieved an improvement of PASI of 100. Onset of action was observed in an early as 6 weeks. No related adverse events or toxicities were observed during the treatment phase or follow up. In this study we demonstrated significant improvement in psoriasis with an orally administered agent with no significant toxicities. While the last decade has seen ~~a~~ remarkably effective new treatments for psoriasis, having an oral administered agent without significant toxicities represents a significant advance in our therapeutic armamentarium.